#obesity drugs

[ follow ]
#obesity-drugs #novo-nordisk #ozempic #weight-loss #pfizer #pharmaceuticals #mergers--acquisitions #drug-pricing
#pfizer
from24/7 Wall St.
2 weeks ago
Medicine

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

Pfizer's diversified portfolio contrasts with Moderna's focus on cost cuts and mRNA technology post-pandemic.
fromFortune
6 months ago
Business

Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune

Pfizer will acquire development-stage obesity drugmaker Metsera for up to $86.25 per share, outbidding Novo Nordisk amid antitrust concerns.
Medicine
from24/7 Wall St.
2 weeks ago

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

Pfizer's diversified portfolio contrasts with Moderna's focus on cost cuts and mRNA technology post-pandemic.
more#pfizer
Medicine
from24/7 Wall St.
1 month ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution is driving biopharma M&A strategies, with companies like Viking Therapeutics and Structure Therapeutics as prime acquisition targets.
#ozempic
more#ozempic
#obesity-drugs
more#obesity-drugs
Medicine
fromwww.theguardian.com
5 months ago

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer's trials

Oral semaglutide failed to slow Alzheimer's progression in two large trials, prompting a sharp share price drop for Novo Nordisk.
fromwww.mediaite.com
6 months ago

MSNBC's Jen Psaki Roasts Trump for 'Nodding Off' in Oval

And when any White House experiences a humiliating defeat. And believe me, I've been part of those, the instinct is often most of the time to change the subject. I mean, roll out a new policy, hold a big event, make any announcement of any kind, basically to get people to talk about anything other than the absolute shellacking that you just took at the polls.
US politics
fromwww.npr.org
6 months ago

White House strikes deals for lower prices on obesity drugs

"We believe these deals, within two years based on our health improvements, we will be budget neutral,"
Public health
Business
fromMedCity News
6 months ago

Pfizer Lawsuits Allege Novo Nordisk's Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News

Pfizer secured regulatory approval for its $4.9B Metsera acquisition, but competing Novo Nordisk bid and related lawsuits may determine if and when the transaction closes.
Medicine
fromwww.theguardian.com
6 months ago

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

Novo Nordisk launched a $9bn unsolicited bid to acquire Metsera, directly challenging Pfizer's existing takeover offer amid competition for obesity-drug assets.
[ Load more ]